Preclinical study of formulated recombinant nucleocapsid protein, the receptor binding domain of the spike protein, and truncated spike (S1) protein as vaccine candidates against COVID-19 in animal models

BACKGROUND: In this pre-clinical study, we designed a candidate vaccine based on severe acute respiratory syndrome-related -coronavirus 2 (SARS-CoV-2) antigens and evaluated its safety and immunogenicity. METHODS: SARS-CoV-2 recombinant protein antigens, including truncated spike protein (SS1, lacki...

Descripción completa

Detalles Bibliográficos
Autores principales: Nazarian, Shahram, Olad, Gholamreza, Abdolhamidi, Raziyeh, Motamedi, Mohammad Javad, Kazemi, Rouhollah, Kordbacheh, Emad, Felagari, Alireza, Olad, Hanieh, Ahmadi, Ali, Bahiraee, Alireza, Farahani, Parisa, Haghighi, Leila, Hassani, Faezeh, Hajhassan, Vahideh, Nadi, Mona, Sheikhi, Abdolkarim, Salimian, Jafar, Amani, Jafar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9222294/
https://www.ncbi.nlm.nih.gov/pubmed/35802999
http://dx.doi.org/10.1016/j.molimm.2022.06.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9222294/
https://www.ncbi.nlm.nih.gov/pubmed/35802999
http://dx.doi.org/10.1016/j.molimm.2022.06.007

Ejemplares similares